Nordic Cancer Hormone Therapy Market (2021–2031)
The Nordic cancer hormone therapy market size is expected to reach US$ 775.5 million by 2031 from US$ 423.7 million in 2024. The market is estimated to record a CAGR of 9.0% from 2025 to 2031.
Report Coverage
- Drug Class: GnRH Analogs, GnRH Antagonists, Androgen Receptor Antagonists, Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Estrogen Receptor Antagonists, Thyroid Hormone Therapy, Other Drug Classes
- Cancer Type: Breast Cancer, Prostate Cancer, Endometrial Cancer, Ovarian Cancer, Thyroid Cancer, Other Cancer Types
- Route of Administration: Oral, Injectable, Implantable
- Sales Channel: Hospitals, Cancer Treatment Centers, Specialty Clinics, Retail Pharmacies
US$ 423.7 Mn
Market size in 2024
US$ 775.5 Mn
Market Size by 2031
9.0%
CAGR, 2025 - 2031
2025-2031
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Nordic Cancer Hormone Therapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Nordic Cancer Hormone Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Nordic Cancer Hormone Therapy Market Regional Analysis
6.2 Nordic Cancer Hormone Therapy Market Revenue 2021-2031 (US$ Million)
6.3 Nordic Cancer Hormone Therapy Market Forecast Analysis
7. Nordic Cancer Hormone Therapy Market Analysis – by Drug Class
7.1 GnRH Analogs
- 7.1.1 Overview
- 7.1.2 GnRH Analogs: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 GnRH Antagonists
- 7.2.1 Overview
- 7.2.2 GnRH Antagonists: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Androgen Receptor Antagonists
- 7.3.1 Overview
- 7.3.2 Androgen Receptor Antagonists: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Aromatase Inhibitors
- 7.4.1 Overview
- 7.4.2 Aromatase Inhibitors: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Selective Estrogen Receptor Modulators
- 7.5.1 Overview
- 7.5.2 Selective Estrogen Receptor Modulators: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Estrogen Receptor Antagonists
- 7.6.1 Overview
- 7.6.2 Estrogen Receptor Antagonists: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Thyroid Hormone Therapy
- 7.7.1 Overview
- 7.7.2 Thyroid Hormone Therapy: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Other Drug Classes
- 7.8.1 Overview
- 7.8.2 Other Drug Classes: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Nordic Cancer Hormone Therapy Market Analysis – by Cancer Type
8.1 Breast Cancer
- 8.1.1 Overview
- 8.1.2 Breast Cancer: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Prostate Cancer
- 8.2.1 Overview
- 8.2.2 Prostate Cancer: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Endometrial Cancer
- 8.3.1 Overview
- 8.3.2 Endometrial Cancer: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Ovarian Cancer
- 8.4.1 Overview
- 8.4.2 Ovarian Cancer: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Thyroid Cancer
- 8.5.1 Overview
- 8.5.2 Thyroid Cancer: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Other Cancer Types
- 8.6.1 Overview
- 8.6.2 Other Cancer Types: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Nordic Cancer Hormone Therapy Market Analysis – by Route of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Injectable
- 9.2.1 Overview
- 9.2.2 Injectable: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Implantable
- 9.3.1 Overview
- 9.3.2 Implantable: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Nordic Cancer Hormone Therapy Market Analysis – by Sales Channel
10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Hospitals: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Cancer Treatment Centers
- 10.2.1 Overview
- 10.2.2 Cancer Treatment Centers: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Specialty Clinics
- 10.3.1 Overview
- 10.3.2 Specialty Clinics: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.4 Retail Pharmacies
- 10.4.1 Overview
- 10.4.2 Retail Pharmacies: Nordic Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. Nordic Cancer Hormone Therapy Market – Nordic Analysis
11.1 Overview
11.2 Nordic- 11.2.1 Nordic Cancer Hormone Therapy Market Breakdown, by Key Country, 2025 and 2031 (%)
- 11.2.1.1 Nordic Cancer Hormone Therapy Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 Sweden: Nordic Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 Sweden: Nordic Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.1.2 Sweden: Nordic Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.1.3 Sweden: Nordic Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.1.4 Sweden: Nordic Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.2 Denmark: Nordic Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 Denmark: Nordic Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.2.2 Denmark: Nordic Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.2.3 Denmark: Nordic Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.2.4 Denmark: Nordic Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.3 Norway: Nordic Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 Norway: Nordic Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.3.2 Norway: Nordic Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.3.3 Norway: Nordic Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.3.4 Norway: Nordic Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.4 Finland: Nordic Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.4.1 Finland: Nordic Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.4.2 Finland: Nordic Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.4.3 Finland: Nordic Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.4.4 Finland: Nordic Cancer Hormone Therapy Market Breakdown, by Sales Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Pfizer Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 AbbVie
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Johnson & Johnson
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Novartis AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 AstraZeneca
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Sanofi
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Eli Lilly and Co
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F. Hoffmann-La Roche Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Astellas Pharma Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Ipsen Pharma
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full Nordic Cancer Hormone Therapy Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.